Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.
Ontology highlight
ABSTRACT: Interventions: CPT-11 150mg/m2 i.v. (day1) Bev 7.5mg/kg i.v. (day1) S-1 80mg/m2 p.o. (day1-14) to be repeated every 3 weeks
Primary outcome(s): Progression Free Survival
Study Design: Single arm Non-randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2621739 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA